News

Axsome Therapeutics (NASDAQ: AXSM) stock jumped more than 10% on June 14 after the company made its latest investor presentation public. The market was reacting to new estimates that suggest peak

Axsome Therapeutics (NASDAQ: AXSM) started out last year as a small up-and-coming biotech company. It finished the year with a more than 100% gain, beating the bear market and crushing the S&P 500

The best biotech growth stocks typically have one clear-cut value driver. This fact is a testament to the extreme difficulty involved in bringing a major new drug to market and subsequently

Artificial intelligence (AI) is getting heaps of attention on Wall Street, but that doesn't mean it's the only innovative investment opportunity right now. Shares of plenty of companies that aren't

Biotech investors like it when one of their companies reports gains in a developmental program, and that was the dynamic behind Tuesday's rise in the share price of Aclaris Therapeutics (NASDAQ:

Biotech growth stocks are inherently risky due to the plethora of competitive, financial, clinical, and regulatory hurdles unique to the industry. Despite these various risk factors, however, most

Shares of Omeros (NASDAQ: OMER) were down 12.9% early Monday afternoon after the clinical-stage biopharmaceutical company released a presentation it made regarding a therapy to treat a rare blood

Sell in May and go away? The old adage hasn't proven to be great advice in 2023. The stock market has risen so far in June and could go even higher.

Three Motley Fool contributors think some stocks

Biotech company Novavax (NASDAQ: NVAX) has fallen from grace over the past year, with the vaccine maker's shares dropping by 84% over the trailing-12-month period. But Wall Street hasn't given up on

Not many stocks are truly capable of generating a 1,000% return on investment within a reasonable time frame. Even so, a fair number of next-generation technology stocks have hit this lofty

Buying a soaring growth stock can be both exciting and risky territory for investors. In the biotech world, all it often takes is news of an approval from the Food and Drug Administration (FDA) or

One of the exciting parts of investing is identifying companies that will offer us the next big thing. This could be a game-changing drug or an exciting technology that may transform healthcare. And

Shares of Apollomics (NASDAQ: APLM) were up more than 11% Friday morning after an analyst initiated coverage on the stock with a buy rating. The clinical-stage biopharmaceutical company focuses on

Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. That's equivalent to a $7 billion drop in market capitalization. 

What's

Shares of the metabolic disease specialist Viking Therapeutics (NASDAQ: VKTX) were up by 6.6% on slightly below-average volume as of 1:56 p.m. ET Wednesday afternoon. The biotech's stock is heating

Investors looking for growth stocks that can make dramatic moves in a short time should look more closely at healthcare. Two stocks in this sector have already doubled this year and could climb much

The next 12 months could be dicey for the economy and the stock market, especially as the U.S. Federal Reserve recently predicted a recession could come by year-end. But even in this environment

Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. I'm talking about Novavax

Shares of the clinical-stage drugmaker Madrigal Pharmaceuticals (NASDAQ: MDGL) were up by 6.2% on elevated volume as of 12:16 p.m. ET Wednesday. The biotech appears to be benefiting from two key

Shares of Akebia Therapeutics (NASDAQ: AKBA) were up more than 10% Tuesday after rising to as high as 13.1% in early trading. The biopharmaceutical company, which specializes in therapies to fight

Equities experienced a bear market in 2022, and although things have improved significantly over the past few months, it's impossible to say whether we are out of the woods. However, some

Buying growth stocks on the cheap can be a great way to build wealth for investors with enough patience. This is because the strategy combines the high return potential of growth investing with the

A significant miss on quarterly earnings combined with a big change in its C-suite put a damper on CymaBay Therapeutics (NASDAQ: CBAY) stock this week. According to data compiled by S&P Global